Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.
about
Chapter 7: PharmacogenomicsGenetic testing for prevention of severe drug-induced skin rashHLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinolClinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosingClinical use of pharmacogenomic tests in 2009Antiretroviral therapy and dyslipidaemia: unlocking the code.MinION: A Novel Tool for Predicting Drug Hypersensitivity?Genetic Markers of the Host in Persons Living with HTLV-1, HIV and HCV InfectionsThe impact of next-generation sequencing technologies on HLA researchPharmacogenetics as a tool to tailor antiretroviral therapy: A reviewNew genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivityEvolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response.Systems pharmacology: network analysis to identify multiscale mechanisms of drug actionIdiosyncratic adverse drug reactions: current conceptsGenetic correlates influencing immunopathogenesis of HIV infectionPerspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbiditiesAbacavir pharmacogenetics--from initial reports to standard of carePharmacogenomics of adverse drug reactionsHarvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactomePathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.Pharmacogenetics and Predictive Testing of Drug Hypersensitivity ReactionsIndividualization of antiretroviral therapy--pharmacogenomic aspectSevere Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical ImplementationThe Importance of Patient-Specific Factors for Hepatic Drug Response and ToxicityChallenges to integrating pharmacogenetic testing into medication therapy managementProgress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicityEfficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-upAbacavir-reactive memory T cells are present in drug naïve individualsComparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 careGenome-Wide Association Study in Immunocompetent Patients with Delayed Hypersensitivity to Sulfonamide AntimicrobialsPrognosis research strategy (PROGRESS) 4: stratified medicine research'Sifting the significance from the data' - the impact of high-throughput genomic technologies on human genetics and health careSide effects of HIV therapyAdverse Drug Reactions in Children: The Double-Edged Sword of Therapeutics.Human leucocyte antigen-adverse drug reaction associations: from a perspective of ethnicity.HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.Pharmacogenomics of off-target adverse drug reactions.Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data.HLA Class I and II alleles, heterozygosity and HLA-KIR interactions are associated with rates of genital HSV shedding and lesions.
P2860
Q21563496-67D62BD1-3F32-420D-A166-EBC4D67FA652Q24202114-4E382E03-125D-46B3-912C-735353D00E74Q24555784-F95C6C18-17A1-42E5-B116-DA1A2BA08EDFQ24626941-448EB569-13BC-4169-9AE2-B959E531D0F1Q24657536-374089C4-0FE3-43D7-83B5-F31CC512C009Q25256933-5973BA9F-3D18-4F9F-A2B4-C1BB09266352Q26744637-EF2FCB98-C082-49B6-89E0-D5B82CD7D4CFQ26768628-3CA5066D-8C3E-4E4B-BD14-C2DC4AC7F264Q26796663-F4BE0447-AB6C-4DB8-B008-39BDC88B6FFFQ26797938-65AB1F00-1A36-446A-9133-68F3F4AACA18Q26800976-755EA370-F60C-4863-9044-FE35977847A6Q26800980-4B39F841-17A2-4DCC-B005-C28907949465Q26824166-FD1822DB-8FEA-409F-A46E-00F046DB1B22Q26824391-67BA1CD9-C95B-4B18-9553-9C6234C4AB89Q26827459-AF972646-9A96-4103-81BE-22DED8170976Q26853274-B760464A-1034-47C7-B3EA-3EC95D71C837Q27008841-8DEB1D59-C3DD-4FA1-A70E-2E69771A39F5Q27015820-4FE8FD7A-A24B-4CD3-B7A8-502A43938081Q27335598-9ACF53CC-14F3-497C-801A-F2AF2BC430CCQ27690772-0085C7E7-D209-4A05-B8FD-E780A3BD36F8Q27692095-411D9A43-716F-4B04-ABA9-6316FA6C26EDQ28066096-A4C08D0A-BF70-4DA1-ADD5-CD9F521ADA92Q28070574-713512B3-839C-41A5-B658-CB08E2C55BA8Q28076600-E92F8740-20F5-418D-A3C1-A9475CFE8F3DQ28080256-E347E21F-A6E3-4FFA-9FF8-5F21AEECB6FEQ28082835-5C9400C0-DA16-4767-A66A-47661C71A6E6Q28083100-2E346A29-E56F-4CB3-B1BC-F2671E1BB8A1Q28538860-581B9087-AF41-4AF6-A810-7D6E82E6D954Q28543405-294FBB92-A4AB-4384-8764-8044D9A8C14CQ28546416-E6AA97DC-0CE8-4E02-A341-77D0F16B41BFQ28550088-98954C0B-0F1D-452E-8B32-0E5E1E04C457Q28709167-D54B47F2-702D-4DC9-A4B5-125A48698F33Q28711804-2752E417-972B-4C62-9821-AB5820CAB670Q29394405-DE2A513A-B5ED-406B-ABAC-242521BE9A26Q30235268-89EF26D8-24FC-4BF6-9F18-B929D9CF419CQ30238992-DCB0AD27-5E8C-4762-8D37-5FB6A3CBF143Q30371340-DCD24330-D6B5-48F9-901A-54F92653D69CQ30400366-7F2CC4F3-B9B7-4C37-8461-245DDB3D090EQ30758299-F7BB164E-2679-4CF8-9079-25C3D7C952B3Q30830481-A3E7DD60-520B-477A-949D-28B72767437F
P2860
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Association between presence o ...... nscriptase inhibitor abacavir.
@ast
Association between presence o ...... nscriptase inhibitor abacavir.
@en
Association between presence o ...... nscriptase inhibitor abacavir.
@nl
type
label
Association between presence o ...... nscriptase inhibitor abacavir.
@ast
Association between presence o ...... nscriptase inhibitor abacavir.
@en
Association between presence o ...... nscriptase inhibitor abacavir.
@nl
prefLabel
Association between presence o ...... nscriptase inhibitor abacavir.
@ast
Association between presence o ...... nscriptase inhibitor abacavir.
@en
Association between presence o ...... nscriptase inhibitor abacavir.
@nl
P2093
P1433
P1476
Association between presence o ...... nscriptase inhibitor abacavir.
@en
P2093
A M Martin
F T Christiansen
P304
P356
10.1016/S0140-6736(02)07873-X
P407
P577
2002-03-01T00:00:00Z